MYL : NASDAQ : Health Care
$30.56 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 6243400.0
08/17/17 - 4:00 PM ET

Financial Analysis


MYLAN NV's gross profit margin for the second quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. MYLAN NV has weak liquidity. Currently, the Quick Ratio is 0.74 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 24.23% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q2 FY17 Q2 FY16
Net Sales ($mil)2962.22560.7
EBITDA ($mil)905.8787.7
EBIT ($mil)497.6484.3
Net Income ($mil)297.0168.4


Balance Sheet Q2 FY17 Q2 FY16
Cash & Equiv. ($mil)876.36518.0
Total Assets ($mil)35506.228836.3
Total Debt ($mil)14989.913483.4
Equity ($mil)12832.910329.9


Profitability Q2 FY17 Q2 FY16
Gross Profit Margin56.2358.53
EBITDA Margin30.5730.76
Operating Margin16.818.91
Sales Turnover0.340.34
Return on Assets1.862.79
Return on Equity5.157.79
Debt Q2 FY17 Q2 FY16
Current Ratio1.353.23
Debt/Capital0.540.57
Interest Expense128.054.4
Interest Coverage3.898.9


Share Data Q2 FY17 Q2 FY16
Shares outstanding (mil)536.12508.42
Div / share0.00.0
EPS0.550.33
Book value / share23.9420.32
Institutional Own % n/a n/a
Avg Daily Volume5853664.05936264.0

Valuation


HOLD. The current P/E ratio indicates a discount compared to an average of 28.08 for the Pharmaceuticals industry and a premium compared to the S&P 500 average of 24.31. For additional comparison, its price-to-book ratio of 1.35 indicates a significant discount versus the S&P 500 average of 3.03 and a significant discount versus the industry average of 16.44. The price-to-sales ratio is well below both the S&P 500 average and the industry average, indicating a discount. Upon assessment of these and other key valuation criteria, MYLAN NV proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
MYL 26.47 Peers 28.08   MYL 6.80 Peers 25.61

Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.

MYL is trading at a valuation on par with its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

MYL is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
MYL 6.18 Peers 14.98   MYL 0.07 Peers 0.61

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

MYL is trading at a significant discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

MYL trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
MYL 1.35 Peers 16.44   MYL -22.30 Peers 25.27

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

MYL is trading at a significant discount to its peers.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, MYL is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
MYL 1.44 Peers 6.45   MYL 20.81 Peers 8.29

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

MYL is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

MYL has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades